



Australian Government

Department of Health and Aged Care

Therapeutic Goods Administration

Case Line Listing

You searched for the following:

Report Date: >01/03/2024 <=01/06/2024

Study Type: Individual patient use

Case Decision: Accepted

Characterisation: Suspect, Interacting

Ingredient Name: cannabidiol, Cannabis sativa, tetrahydrocannabinol, Tetrahydrocannabinol (THC), CANNABINOL

Number of Reports: 111

22 July 2024

Page 1 of 11

© Commonwealth of Australia 2017.

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice and all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given specific written permission from the Commonwealth to do so. Requests and enquiries concerning reproduction and rights are to be sent to the TGA Copyright Officer, Therapeutic Goods Administration, PO Box 100, Woden ACT 2606 or emailed to <tga.copyright@tga.gov.au>.

Limitations of the data

This document contains information from reports of adverse events that the TGA has received in relation to therapeutic goods. It does not contain all known information, and an assessment of the safety of a medicine cannot be made based on this information.

Causality

- The reports received by the TGA contain suspected associations that reflect the observations of an individual reporter. The reporter may be a health professional, a sponsor, or a member of the public.
- Adverse events are suspected of being related to a therapeutic good, but this relationship is usually not certain - the symptom may be related to the underlying illness or to other factors.
- There might be no relationship between the adverse event and the medicine - it may be a coincidence that the adverse event occurred when the medicine was taken.

Case no.	Report Date	Sex	Age	Medicine reported as being taken (Onset Time in Days)	Reaction
803766	04/03/2024	Male	39	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Back pain; Hyperhidrosis; Rash; Vitreous floaters
803856	04/03/2024	Female	35	§22 (cannabidiol ; delta-9-tetrahydrocannabinol) - Suspect §22	Abdominal discomfort; Nausea
803943	05/03/2024	Female	57	Trade Name Not Specified (tetrahydrocannabinol) - Suspect §22	Paranoia; Psychotic disorder; Suicidal ideation
803956	05/03/2024	Female	26	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cannabinoid hyperemesis syndrome
804131	06/03/2024	Male	66	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22; §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Throat irritation
804132	06/03/2024	Male	43	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Oropharyngeal pain
804232	07/03/2024	Male	61	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cough
804233	07/03/2024	Male	36	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Anxiety
804235	07/03/2024	Male	52	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Mood altered
804333	08/03/2024	Female	20	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Paranoia
804450	11/03/2024	Male	32	§22 (tetrahydrocannabinol) - Suspect §22	Device breakage
804493	12/03/2024	Male	29	Trade Name Not Specified (tetrahydrocannabinol) - Suspect §22	Bipolar disorder; Mania; Paranoia; Psychotic disorder
804495	12/03/2024	Male	<1	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Headache; Nausea
804533	12/03/2024	Female	27	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Headache
804536	12/03/2024	Male	32	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Somnolence
804537	12/03/2024	Female	64	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cough

804538	12/03/2024	Female	71	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Dry mouth
804539	12/03/2024	Male	53	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Abdominal discomfort
804540	12/03/2024	Male	28	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Somnolence
804641	13/03/2024	Female	32	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Anxiety
804642	13/03/2024	Male	52	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22 ; §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cough
804724	14/03/2024	Male	-	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Product complaint; Product container issue
804725	14/03/2024	Female	-	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Product complaint; Product contamination microbial
804831	15/03/2024	Female	56	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Headache
804832	15/03/2024	Male	50	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Dyschezia
804925	18/03/2024	Female	48	§22 (cannabidiol) - Suspect §22	Diarrhoea
805112	19/03/2024	Male	59	§22 (rosuvastatin calcium) - Concomitant §22 ; §22 (ezetimibe) - Concomitant §22 ; §22 (Cannabis sativa ; tetrahydrocannabinol) - Suspect §22 ; §22 (tetrahydrocannabinol) - Suspect §22 ; §22 (metoprolol tartrate) - Concomitant §22 ; §22 (desvenlafaxine) - Concomitant §22 ; §22 (buprenorphine hydrochloride ; naloxone hydrochloride dihydrate) - Concomitant §22 ; Trade Name Not Specified (clonazepam) - Concomitant §22 ; Trade Name Not Specified (clopidogrel) - Concomitant §22 ; Trade Name Not Specified (mirtazapine) - Concomitant §22 ; Trade Name Not Specified (pantoprazole sodium sesquihydrate) -	Product impurity; Productive cough

				Concomitant ^{s22} ; Trade Name Not Specified (pramipexole dihydrochloride monohydrate) - Concomitant ^{s22} ; ^{s22} ^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22} ; ^{s22} ^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	
805129	19/03/2024	Male	32	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Sleep inertia
805298	21/03/2024	Male	-	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Product complaint; Product physical issue
805310	21/03/2024	Male	45	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Cough; Somnolence
805413	22/03/2024	Female	28	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Cough
805414	22/03/2024	Male	31	^{s22} (cannabidiol ; tetrahydrocannabinol ; Tetrahydrocannabinol (THC)) - Suspect ^{s22}	Somnolence
805559	25/03/2024	Male	25	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Headache
805653	26/03/2024	Female	50	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Cough; Oropharyngeal pain
805747	27/03/2024	Male	31	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Malaise
805748	27/03/2024	Male	26	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Cough
805943	29/03/2024	Male	40	^{s22} (cannabidiol ; tetrahydrocannabinol ; Tetrahydrocannabinol (THC)) - Suspect ^{s22}	Vertigo
806211	03/04/2024	Male	58	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Product odour abnormal; Product taste abnormal
806222	03/04/2024	Male	56	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Headache
806327	04/04/2024	Male	58	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Drug ineffective
806380	04/04/2024	Female	53	^{s22} (cannabidiol ; tetrahydrocannabinol) - Suspect ^{s22}	Headache

806557	08/04/2024	Male	46	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Vomiting
806559	08/04/2024	Male	33	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22 §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Anxiety
806560	08/04/2024	Female	45	§22 (cannabidiol) - Suspec §22	Nausea
806562	08/04/2024	Male	42	§22 (cannabidiol ; tetrahydrocannabinol) - Suspec §22	Somnolence
806628	09/04/2024	Female	31	§22 (cannabidiol ; tetrahydrocannabinol) - Concomitant §22; §22 (ibuprofen) - Concomitant §22; §22 paracetamol - Concomitant §22; Trade Name Not Specified (amitriptyline) - Concomitant §22; Trade Name Not Specified (gabapentin) - Concomitant §22; §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cognitive disorder; Dissociative disorder; Dizziness; Vision blurred
806696	09/04/2024	Male	17	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Hallucination; Psychotic disorder; Sleep deficit; Tachycardia
806700	09/04/2024	Female	38	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Anxiety
806797	10/04/2024	Female	36	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Apathy; Malaise
806894	11/04/2024	Male	52	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Somnolence
806896	11/04/2024	Female	34	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Nausea; Somnolence
806898	11/04/2024	Male	42	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Fatigue
806974	12/04/2024	Unspecified	-	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Psychotic disorder
807122	15/04/2024	Male	71	§22 cannabidiol ; delta-9-tetrahydrocannabinol) - Suspect §22	Dry mouth; Fatigue
807265	16/04/2024	Male	27	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Hallucination, auditory

807468	18/04/2024	Male	49	Trade Name Not Specified (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Hallucination; Paranoia; Psychotic disorder
807489	18/04/2024	Female	20	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Nausea
807561	19/04/2024	Female	51	§22 (Blueberry Kush) (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Chills
807590	20/04/2024	Male	29	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Product colour issue; Product complaint; Product packaging quantity issue; Product taste abnormal
807639	22/04/2024	Unspecified	-	§22 (cannabidiol) - Suspect §22	Affective disorder; Aggression; Product complaint; Product quality issue; Therapeutic response decreased
807689	22/04/2024	Female	73	§22 (cannabidiol) - Suspect §22	Depressed mood; Somnolence
807690	22/04/2024	Male	31	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22 §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Restlessness
807691	22/04/2024	Male	24	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Cough
807762	23/04/2024	Male	38	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Abdominal discomfort
807764	23/04/2024	Male	52	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22 §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Abdominal discomfort
807765	23/04/2024	Male	33	§22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22; §22 §22 (cannabidiol ; tetrahydrocannabinol) - Suspect §22	Nausea

807768	23/04/2024	Male	68	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Chronic obstructive pulmonary disease
807847	24/04/2024	Female	34	Trade Name Not Specified (cannabidiol) - Interacting s22; Trade Name Not Specified (levothyroxine sodium) - Interacting s22	Hyperthyroidism; Thyroxine free increased
807867	24/04/2024	Female	83	s22 (cannabidiol ; tetrahydrocannabinol ; Tetrahydrocannabinol (THC)) - Suspect s22, s22; s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Brain fog
807870	24/04/2024	Female	19	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Abdominal discomfort
807932	25/04/2024	Male	31	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety
807934	25/04/2024	Male	34	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
807989	26/04/2024	Male	26	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Headache
807990	26/04/2024	Male	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Product colour issue; Product complaint; Product formulation issue
807992	26/04/2024	Unspecified	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Expired product administered; Product complaint; Product quality issue
808015	26/04/2024	Male	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Product complaint; Product expiration date issue
808034	27/04/2024	Female	31	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety
808065	29/04/2024	Male	-	s22 cannabidiol ; tetrahydrocannabinol) - Suspect s22	Dysgeusia; Product colour issue; Product complaint; Product odour abnormal; Product quality issue
808121	29/04/2024	Female	33	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Cough; Dizziness

808122	29/04/2024	Male	44	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
808123	29/04/2024	Male	34	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Oropharyngeal pain
808163	30/04/2024	Male	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Product complaint; Product quality issue
808204	30/04/2024	Female	35	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Nausea
808205	30/04/2024	Female	27	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
808206	30/04/2024	Male	45	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
808282	01/05/2024	Male	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Product complaint; Product odour abnormal
808300	01/05/2024	Male	56	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Oropharyngeal pain
808392	02/05/2024	Male	41	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety
808393	02/05/2024	Male	37	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Tremor
808673	03/05/2024	Female	63	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Headache; Hot flush
808843	06/05/2024	Female	29	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety
809039	07/05/2024	Female	43	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Nausea
809083	08/05/2024	Male	31	Trade Name Not Specified (cannabidiol) - Suspect s22	Product prescribing issue; Schizophrenia
809194	09/05/2024	Male	45	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22; s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety; Depression; Drug ineffective

809198	09/05/2024	Male	54	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22 s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety; Condition aggravated; Drug ineffective; Insomnia
809214	09/05/2024	Male	37	s22 Cannabis Flower (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Cough
809346	10/05/2024	Female	27	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
809347	10/05/2024	Male	61	s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Thinking abnormal
809349	10/05/2024	Female	39	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Diarrhoea
809531	13/05/2024	Female	-	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Product complaint; Product dispensing error
809548	13/05/2024	Male	48	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Lethargy
809703	14/05/2024	Female	47	Trade Name Not Specified (tetrahydrocannabinol) - Suspect s22	Anxiety; Depression
809845	14/05/2024	Female	20	s22 (cannabidiol ; delta-9- tetrahydrocannabinol) - Suspect s22; s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Anxiety; Insomnia
810027	15/05/2024	Female	45	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22; s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22 s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22; Trade Name Not Specified (lamotrigine) - Concomitant s22 Trade Name Not Specified (methylphenidate hydrochloride) - Concomitant s22 Trade Name Not Specified (venlafaxine hydrochloride) - Concomitant s22	Abnormal behaviour; Delusion of grandeur; Depression; Mood altered
810652	21/05/2024	Male	61	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Panic attack

810761	22/05/2024	Male	63	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Mouth ulceration; Myalgia
810961	24/05/2024	Male	44	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Nausea
810962	24/05/2024	Male	32	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Somnolence
811562	31/05/2024	Male	53	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Abdominal discomfort
811563	31/05/2024	Male	43	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Headache
811565	31/05/2024	Female	65	s22 (cannabidiol ; tetrahydrocannabinol) - Suspect s22	Cough